Physician profile
Nora Barsony
NPI 1376648568
$120,960.45
in general payments reported to CMS, 2019-2025
53 companies · $15K in 2025
The $15K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $16K · 2021: $12K · 2022: $17K · 2023: $16K · 2024: $19K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,850 · Travel and Lodging: $1,525 · Consulting Fee: $788 · Education: $8.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,308.13 |
| Food and Beverage | $11,155.10 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,850.00 |
| Travel and Lodging | $1,525.00 |
| Consulting Fee | $787.50 |
| Education | $8.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $34,161.29 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Lilly USA, LLC | $32,842.98 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,155.97 | 2019-2023 | Jardiance |
| Cequr Corporation | $7,889.82 | 2024-2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $7,411.16 | 2019-2025 | |
| Novo Nordisk INC | $2,061.59 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Corcept Therapeutics | $1,773.38 | 2019-2025 | Korlym |
| Amgen INC. | $1,238.49 | 2019-2025 | Evenity, Tepezza, Repatha |
| Astrazeneca Pharmaceuticals Lp | $1,235.37 | 2019-2022 | |
| Mannkind Corporation | $877.55 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $664.49 | 2021-2025 | |
| Medtronic, INC. | $632.99 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Dexcom, INC. | $487.62 | 2021-2025 | Dexcom G6 Transmitter |
| Treace Medical Concepts, INC. | $450.00 | 2024 | |
| Insulet Corporation | $431.13 | 2019-2025 | Omnipod, Omnipod |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $317.20 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Amneal Pharmaceuticals LLC | $305.56 | 2020-2025 | Unithroid |
| Radius Health, INC. | $301.82 | 2019-2021 | |
| Abbvie INC. | $263.01 | 2019-2024 | Synthroid |
| Merck Sharp & Dohme LLC | $255.02 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $216.51 | 2019-2024 | Spravato |
| Recordati_rare_diseases_inc. | $216.42 | 2021-2025 | Isturisa, Signifor Lar |
| Chiesi USA, INC. | $199.68 | 2024-2025 | Mycapssa |
| Intuity Medical INC | $192.97 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Amryt Pharma Holdings Ltd | $184.25 | 2022 | |
| Amarin Pharma, INC. | $170.98 | 2019-2022 | |
| Shire North American Group INC | $167.69 | 2019 | |
| Zealand Pharma US, INC. | $156.00 | 2020-2021 | |
| Nevro Corp. | $149.68 | 2022-2024 | Senza |
| Ibsa Pharma INC. | $144.18 | 2019-2025 | Licart, Tirosint, Tirosint |
| Amphastar Pharmaceuticals, INC. | $143.93 | 2024-2025 | |
| Argenx US, INC. | $125.00 | 2025 | Vyvgart |
| Valeritas, INC. | $121.99 | 2019 | |
| Ascendis Pharma Endocrinology INC | $102.44 | 2024-2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $97.51 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Scientific Affairs, LLC | $85.64 | 2019 | |
| Alexion Pharmaceuticals, INC. | $76.72 | 2019 | |
| Pfizer INC. | $69.12 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $66.47 | 2022 | |
| Sequel Med Tech, LLC | $60.17 | 2025 | Twiist |
| Almatica Pharma LLC | $59.54 | 2024 | Teriparatide, Loreev Xr |
| Esperion Therapeutics, INC. | $57.47 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $53.65 | 2020-2021 | |
| Becton, Dickinson and Company | $48.90 | 2019 | |
| Lifescan, INC. | $42.88 | 2019 | |
| Echosens North America, INC. | $41.88 | 2025 | Fibroscan |
| Chiasma, INC. | $29.53 | 2021 | |
| Gilead Sciences, INC. | $29.26 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $22.16 | 2022 | |
| Horizon Therapeutics Plc | $21.80 | 2021 | |
| Ascensia Diabetes Care US INC. | $20.00 | 2022 | |
| Madrigal Pharmaceuticals | $17.39 | 2025 | Rezdiffra |
| Roche Diabetes Care, INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Barsony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.